Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by westcoast1000on Nov 16, 2022 2:17pm
214 Views
Post# 35104282

RE:Excellent Interview with Matt Coffey - June 2021

RE:Excellent Interview with Matt Coffey - June 2021Proboscises posted this note below on Nov 11.

I went to spotify and found it and listened through. This is the most revealing and remarkable interview or news piece I have ever encountered about ONCY. It clearly explains the twists and turns in the thinking, science context, and assorted trials and why the seem to all have surprising results. First they were surprisingly bad, compared to what they thought would happen. After they began to appreciate ONCY as an I/O agent and not a lytic agent, they started getting results that were surprisingly good. After listening to this whole interview, which was conducted in 2021, I now finally have a much better understanding of the twists and turns to get to where we are now.

I also can see that pure luck has played an enormous role here this process, as well as the evolution of I/O understanding the role of folks like Richard Vile.

I also realize the role of dumb luck that got me into what should have been a failed biotech that is now on the verge of greatness. The strategy they started with would have died if not for scientific and pharmacological changes in the world, and thus their fortunate guidance from the FDA, input from Vile etc. .

Again, no one can deny the power of our recent results. 
<< Previous
Bullboard Posts
Next >>